Severe COVID-19

Authors

Arpan H. Chawala, Division of Infectious Diseases, Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USAFollow
Shivam Gulati, Division of Infectious Diseases, Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USAFollow
Bettina Sinanova, Washington Health Institute, Washington, D.C.Follow
Jose Bordon, Washington Health Institute, Washington, D.C.Follow

Funder

The author(s) received no specific funding for this work.

Abstract

Introduction: There is substantial variation in the clinical characteristics and outcomes of severe coronavirus disease (COVID-19), making it difficult to do an optimal assessment of this condition. We reviewed the current English literature to identify the findings concerning the baseline characteristics and health outcomes of patients with severe COVID-19, primarily those with acute respiratory distress syndrome (ARDS).

Methods: We examined only studies that assessed patients with confirmed COVID-19 by reverse transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with at least one of the following severity criteria: treated in the intensive care unit (ICU), ARDS, and/or invasive mechanical ventilation (IMV) treatment. We assessed the quality of the studies according to the National Heart, Lung and Blood Institute study quality assessment tools.

Results: Seven of 39 studies fulfilled the inclusion criteria. These seven studies included a total 1,863 patients; the median age was 63.5 years (range 49–70). A total 370 (19.8%) were females. Four studies were from the USA, two from China and one from Italy. Comorbidities were reported in six studies. Fever was reported in five studies and was present in 159 out of 272 patients. Cough and shortness of breath (SOB) were reported in four studies, present in 111 out of 142 and 100 out of 142 patients, respectively. The median total lymphocytes was reported in five studies with a range of 400–889/ul. IMV ranged from 15% to 100%, and mortality ranged from 14.6% to 88%. In a subgroup analysis by country, patients from the US showed more comorbidities and higher percentages of IMV and mortality. The mean assessment quality score of the seven studies was 5 out of a maximum 9.

Conclusions: Severe COVID-19 was predominantly seen in male patients who were 60 years or older and was associated with comorbidities. Most of the patients were admitted to the ICU and needed IMV support due to ARDS, and the overall mortality rate had a range of 14.6–88%.

DOI

10.18297/jri/vol4/iss1/55

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

Recommended Citation

Chawala, Arpan H.; Gulati, Shivam; Sinanova, Bettina; and Bordon, Jose (2020) "Severe COVID-19," The University of Louisville Journal of Respiratory Infections: Vol. 4 : Iss. 1 , Article 55.
DOI: https://doi.org/10.18297/jri/vol4/iss1/55
Available at: https://ir.library.louisville.edu/jri/vol4/iss1/55